NCT00450892 - Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer | Biotech Hunter

Enrollment

129

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions

Breast Cancer

Interventions

DRUG

docetaxel+lapatinib

3 cycles of docetaxel (100 mg/m²) + lapatinib (1000 mg/d) followed by 3 cycles of FEC

DRUG

docetaxel + trastuzumab

3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule followed by 3 cycles of FEC 100

DRUG

docetaxel + trastuzumab + lapatinib

"3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule~+lapatinib (1000 mg/d) followed by 3 cycles of FEC 100"

Trial Locations (15)

C.H.U. Sart-Tilman, Liège

Clinique Sainte Elisabeth, Namur

Institut Bergonie, Bordeaux

Institut Bergonié, Bordeaux

CHRU de Limoges, Limoges

Centre Leon Berard, Lyon

CRLC Val D'Aurelle, Montpellier

Centre Henri Becquerel, Rouen

Hopital Rene Huguenin - Institut Curie, Saint-Cloud

Centre Paul Strauss, Strasbourg

Institut Gustave Roussy, Villejuif

The Institute Of Oncology, Ljubljana

Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie, Geneva

Centre Hospitalier Universitaire Vaudois, Lausanne

Western General Hospital, Edinburgh